Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 219

1.

Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial.

Dangas GD, Claessen BE, Mehran R, Xu K, Stone GW.

EuroIntervention. 2013 Jan 22;8(9):1033-9. doi: 10.4244/EIJV8I9A159.

2.

Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.

Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL; SPIRIT III Investigators.

Circulation. 2009 Feb 10;119(5):680-6. doi: 10.1161/CIRCULATIONAHA.108.803528. Epub 2009 Jan 26.

3.

Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.

Musumeci G, Rossini R, Lettieri C, Capodanno D, Romano M, Rosiello R, Guagliumi G, Valsecchi O, Gavazzi A, Angiolillo DJ.

Catheter Cardiovasc Interv. 2012 Sep 1;80(3):395-405. doi: 10.1002/ccd.23337. Epub 2012 Jan 10.

PMID:
22109961
4.
5.

6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.

Gilard M, Barragan P, Noryani AA, Noor HA, Majwal T, Hovasse T, Castellant P, Schneeberger M, Maillard L, Bressolette E, Wojcik J, Delarche N, Blanchard D, Jouve B, Ormezzano O, Paganelli F, Levy G, Sainsous J, Carrie D, Furber A, Berland J, Darremont O, Le Breton H, Lyuycx-Bore A, Gommeaux A, Cassat C, Kermarrec A, Cazaux P, Druelles P, Dauphin R, Armengaud J, Dupouy P, Champagnac D, Ohlmann P, Endresen K, Benamer H, Kiss RG, Ungi I, Boschat J, Morice MC.

J Am Coll Cardiol. 2015 Mar 3;65(8):777-86. doi: 10.1016/j.jacc.2014.11.008. Epub 2014 Nov 16.

6.

Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Chen KY, Rha SW, Li YJ, Poddar KL, Jin Z, Minami Y, Wang L, Kim EJ, Park CG, Seo HS, Oh DJ, Jeong MH, Ahn YK, Hong TJ, Kim YJ, Hur SH, Seong IW, Chae JK, Cho MC, Bae JH, Choi DH, Jang YS, Chae IH, Kim CJ, Yoon JH, Chung WS, Seung KB, Park SJ; Korea Acute Myocardial Infarction Registry Investigators.

Circulation. 2009 Jun 30;119(25):3207-14. doi: 10.1161/CIRCULATIONAHA.108.822791. Epub 2009 Jun 15.

7.

Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.

Cassese S, De Luca G, Villari B, Berti S, Bellone P, Alfieri A, Montinaro A, Quaranta G, Marraccini P, Piscione F; MATRIX Study Investigators.

Catheter Cardiovasc Interv. 2012 Sep 1;80(3):408-16. doi: 10.1002/ccd.23223. Epub 2011 Nov 9.

PMID:
21735531
8.

Late and very late drug-eluting stent thrombosis in the immediate postoperative period after antiplatelet withdrawal: a retrospective study.

Omar HR, Sprenker C, Karlnoski R, Camporesi EM, Mangar D.

Ther Adv Cardiovasc Dis. 2014 Oct;8(5):185-92. doi: 10.1177/1753944714542592. Epub 2014 Jul 10.

PMID:
25015068
10.

Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations.

Jeger RV, Pfisterer ME, Sørensen R, von Felten S, Alber H, Bonetti PO, Eberli F, Erne P, Pedrazzini G, Rickli H, Galatius S, Kaiser CA; BASKET and BASKET-PROVE investigators.

Am Heart J. 2014 Nov;168(5):698-705. doi: 10.1016/j.ahj.2014.07.019. Epub 2014 Jul 30.

PMID:
25440798
11.
12.

Simultaneous two-vessel very-late stent thrombosis of everolimus-eluting stents.

Puri A, Saireddy R, McClean D.

J Invasive Cardiol. 2013 Mar;25(3):E48-50.

13.

Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study).

Tanzilli G, Greco C, Pelliccia F, Pasceri V, Barillà F, Paravati V, Pannitteri G, Gaudio C, Mangieri E.

Am J Cardiol. 2009 Nov 15;104(10):1357-61. doi: 10.1016/j.amjcard.2009.07.002. Epub 2009 Sep 26.

PMID:
19892050
14.

Very late thrombosis of a paclitaxel-eluting stent after 72 months in a patient on dual anti-platelet therapy.

Subban V, Kalidoss L, Sankardas MA.

Cardiovasc J Afr. 2012 Apr 12;23(3):e9-11. doi: 10.5830/CVJA-2011-022.

15.

Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.

Tada T, Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Byrne RA, Kastrati A, Kadota K, Iwabuchi M, Shizuta S, Tazaki J, Shiomi H, Abe M, Ehara N, Mizoguchi T, Mitsuoka H, Inada T, Araki M, Kaburagi S, Taniguchi R, Eizawa H, Nakano A, Suwa S, Takizawa A, Nohara R, Fujiwara H, Mitsudo K, Nobuyoshi M, Kita T, Kimura T; CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators.

Circ Cardiovasc Interv. 2012 Jun;5(3):381-91. doi: 10.1161/CIRCINTERVENTIONS.111.967463. Epub 2012 May 22.

16.

Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents.

Kandzari DE, Barker CS, Leon MB, Mauri L, Wijns W, Fajadet J, Mehran R.

JACC Cardiovasc Interv. 2011 Oct;4(10):1119-28. doi: 10.1016/j.jcin.2011.06.017.

17.

Current management and quality of life of patients with acute coronary syndrome undergoing percutaneous coronary intervention in Greece: 12-Month results from antiplatelet therapy observational study II (APTOR II).

Pavlides G, Drossinos V, Dafni C, Altsitzoglou P, Antoniadis A, Manolis AS, Tsioufis C, Goudevenos I, Kochiadakis G, Alexopoulos D.

Hellenic J Cardiol. 2013 Jul-Aug;54(4):255-63.

18.

Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial.

Collet JP, Silvain J, Barthélémy O, Rangé G, Cayla G, Van Belle E, Cuisset T, Elhadad S, Schiele F, Lhoest N, Ohlmann P, Carrié D, Rousseau H, Aubry P, Monségu J, Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Beygui F, Vicaut E, Montalescot G; ARCTIC investigators.

Lancet. 2014 Nov 1;384(9954):1577-85. doi: 10.1016/S0140-6736(14)60612-7. Epub 2014 Jul 15.

PMID:
25037988
19.

Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study.

Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Berger PB, Iakovou I, Dangas G, Waksman R, Antoniucci D, Sartori S, Krucoff MW, Hermiller JB, Shawl F, Gibson CM, Chieffo A, Alu M, Moliterno DJ, Colombo A, Pocock S.

Lancet. 2013 Nov 23;382(9906):1714-22. doi: 10.1016/S0140-6736(13)61720-1. Epub 2013 Sep 1.

PMID:
24004642
20.

Frequency, mechanisms, and implications of late peri-stent contrast staining: analysis (from the HORIZONS-AMI Trial).

Yakushiji T, Inaba S, Maehara A, Brener SJ, Witzenbichler B, Guagliumi G, Brodie BR, Kellett MA Jr, Xu K, Mehran R, Mintz GS, Stone GW.

Am J Cardiol. 2013 Jun 1;111(11):1587-92. doi: 10.1016/j.amjcard.2013.01.329. Epub 2013 Mar 13.

PMID:
23497778

Supplemental Content

Support Center